Asia Pacific Liver Disease Diagnostics Market By End User (Hospitals, Laboratories and Other End Users), By Diagnosis Technique (Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques), By Country, Industry Analysis and Forecast, 2020 - 2026
The Asia Pacific Liver Disease Diagnostics Market would witness market growth of 7.9% CAGR during the forecast period (2020-2026).
The market in the Asia Pacific is projected to rise significantly during the forecast period. The growing geriatric population and awareness of regular check-ups are contributing to the growth of the liver disease diagnostics market in this country. In addition, it is projected that the regulatory acceptance of emerging technology that can be incorporated with imaging systems would fuel regional growth. For example, in August 2018, LiverMultiScan obtained approval from Therapeutic Goods Administration (TGA) to treat patients with highly prevalent diseases in Australia such as NAFLD and NASH.
An unhealthy diet, high-stress levels, and unorganized lifestyle patterns are the main drivers of the liver disease treatment market. Overweight and obesity rates in developing countries have increased dramatically, raising the chances of liver disease. In addition, increased alcohol consumption has fueled an increase in fatal liver disease. These factors also increased incidences of liver disease, which will fuel the growth of the liver disease treatment market in the future. Different strategies for the development of emerging technologies to advance patient care are being applied by key players.
Aging is a condition in which a person is gradually losing the ability to maintain homeostasis due to structural alteration or dysfunction. Aging is a major risk factor for the majority of chronic diseases. Aging has been shown not only to increase the vulnerability of acute liver injury but also to increase the susceptibility of fibrotic reactions. Aging is associated with the severity and poor prognosis of various diseases of the liver, including non-alcoholic fatty liver disease, alcoholic liver disease, hepatitis C, and liver transplantation.
Structural dysfunction or modification due to aging primarily contributes to diseases of the liver. According to the National Institute of Aging, the geriatric population is expected to grow by 86% by 2050. Increased rates of the geriatric population have resulted in an increase in the incidence of liver disease, which has further increased the demand for the liver disease treatment market.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited
Scope of the Study
Market Segmentation:
By End User
The market in the Asia Pacific is projected to rise significantly during the forecast period. The growing geriatric population and awareness of regular check-ups are contributing to the growth of the liver disease diagnostics market in this country. In addition, it is projected that the regulatory acceptance of emerging technology that can be incorporated with imaging systems would fuel regional growth. For example, in August 2018, LiverMultiScan obtained approval from Therapeutic Goods Administration (TGA) to treat patients with highly prevalent diseases in Australia such as NAFLD and NASH.
An unhealthy diet, high-stress levels, and unorganized lifestyle patterns are the main drivers of the liver disease treatment market. Overweight and obesity rates in developing countries have increased dramatically, raising the chances of liver disease. In addition, increased alcohol consumption has fueled an increase in fatal liver disease. These factors also increased incidences of liver disease, which will fuel the growth of the liver disease treatment market in the future. Different strategies for the development of emerging technologies to advance patient care are being applied by key players.
Aging is a condition in which a person is gradually losing the ability to maintain homeostasis due to structural alteration or dysfunction. Aging is a major risk factor for the majority of chronic diseases. Aging has been shown not only to increase the vulnerability of acute liver injury but also to increase the susceptibility of fibrotic reactions. Aging is associated with the severity and poor prognosis of various diseases of the liver, including non-alcoholic fatty liver disease, alcoholic liver disease, hepatitis C, and liver transplantation.
Structural dysfunction or modification due to aging primarily contributes to diseases of the liver. According to the National Institute of Aging, the geriatric population is expected to grow by 86% by 2050. Increased rates of the geriatric population have resulted in an increase in the incidence of liver disease, which has further increased the demand for the liver disease treatment market.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited
Scope of the Study
Market Segmentation:
By End User
- Hospitals, Laboratories and Other End Users
- Imaging
- Biopsy
- Endoscopy
- Laboratory tests and
- Other Diagnosis Techniques
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Boston Scientific Corporation
- Siemens AG (Siemens Healthineers)
- Bayer AG
- Merck & Co., Inc.
- Sanofi S.A.
- Novartis AG
- Pfizer, Inc.
- Randox laboratories limited
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Liver Disease Diagnostics Market, by End User
1.4.2 Asia Pacific Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 Asia Pacific Liver Disease Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER
3.1 Asia Pacific Hospitals Market by Country
3.2 Asia Pacific Laboratories Market by Country
3.3 Asia Pacific Other End Users Market by Country
CHAPTER 4. ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE
4.1 Asia Pacific Imaging Market by Country
4.2 Asia Pacific Biopsy Market by Country
4.3 Asia Pacific Endoscopy Market by Country
4.4 Asia Pacific Laboratory tests Market by Country
4.5 Asia Pacific Other Diagnosis Techniques Market by Country
CHAPTER 5. ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY
5.1 China Liver Disease Diagnostics Market
5.1.1 China Liver Disease Diagnostics Market by End User
5.1.2 China Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Japan Liver Disease Diagnostics Market
5.2.1 Japan Liver Disease Diagnostics Market by End User
5.2.2 Japan Liver Disease Diagnostics Market by Diagnosis Technique
5.3 India Liver Disease Diagnostics Market
5.3.1 India Liver Disease Diagnostics Market by End User
5.3.2 India Liver Disease Diagnostics Market by Diagnosis Technique
5.4 South Korea Liver Disease Diagnostics Market
5.4.1 South Korea Liver Disease Diagnostics Market by End User
5.4.2 South Korea Liver Disease Diagnostics Market by Diagnosis Technique
5.5 Singapore Liver Disease Diagnostics Market
5.5.1 Singapore Liver Disease Diagnostics Market by End User
5.5.2 Singapore Liver Disease Diagnostics Market by Diagnosis Technique
5.6 Malaysia Liver Disease Diagnostics Market
5.6.1.1.1 Malaysia Liver Disease Diagnostics Market by End User
5.6.2 Malaysia Liver Disease Diagnostics Market by Diagnosis Technique
5.7 Rest of Asia Pacific Liver Disease Diagnostics Market
5.7.1 Rest of Asia Pacific Liver Disease Diagnostics Market by End User
5.7.2 Rest of Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
CHAPTER 6. COMPANY PROFILES
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Randox Laboratories Limited
6.10.1 Company Overview
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Liver Disease Diagnostics Market, by End User
1.4.2 Asia Pacific Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 Asia Pacific Liver Disease Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER
3.1 Asia Pacific Hospitals Market by Country
3.2 Asia Pacific Laboratories Market by Country
3.3 Asia Pacific Other End Users Market by Country
CHAPTER 4. ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE
4.1 Asia Pacific Imaging Market by Country
4.2 Asia Pacific Biopsy Market by Country
4.3 Asia Pacific Endoscopy Market by Country
4.4 Asia Pacific Laboratory tests Market by Country
4.5 Asia Pacific Other Diagnosis Techniques Market by Country
CHAPTER 5. ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY
5.1 China Liver Disease Diagnostics Market
5.1.1 China Liver Disease Diagnostics Market by End User
5.1.2 China Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Japan Liver Disease Diagnostics Market
5.2.1 Japan Liver Disease Diagnostics Market by End User
5.2.2 Japan Liver Disease Diagnostics Market by Diagnosis Technique
5.3 India Liver Disease Diagnostics Market
5.3.1 India Liver Disease Diagnostics Market by End User
5.3.2 India Liver Disease Diagnostics Market by Diagnosis Technique
5.4 South Korea Liver Disease Diagnostics Market
5.4.1 South Korea Liver Disease Diagnostics Market by End User
5.4.2 South Korea Liver Disease Diagnostics Market by Diagnosis Technique
5.5 Singapore Liver Disease Diagnostics Market
5.5.1 Singapore Liver Disease Diagnostics Market by End User
5.5.2 Singapore Liver Disease Diagnostics Market by Diagnosis Technique
5.6 Malaysia Liver Disease Diagnostics Market
5.6.1.1.1 Malaysia Liver Disease Diagnostics Market by End User
5.6.2 Malaysia Liver Disease Diagnostics Market by Diagnosis Technique
5.7 Rest of Asia Pacific Liver Disease Diagnostics Market
5.7.1 Rest of Asia Pacific Liver Disease Diagnostics Market by End User
5.7.2 Rest of Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
CHAPTER 6. COMPANY PROFILES
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Randox Laboratories Limited
6.10.1 Company Overview
LIST OF TABLES
TABLE 1 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 2 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 3 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 4 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 5 ASIA PACIFIC HOSPITALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 ASIA PACIFIC HOSPITALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 ASIA PACIFIC LABORATORIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 ASIA PACIFIC LABORATORIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 ASIA PACIFIC OTHER END USERS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 ASIA PACIFIC OTHER END USERS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 12 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 13 ASIA PACIFIC IMAGING MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 ASIA PACIFIC IMAGING MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 ASIA PACIFIC BIOPSY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 ASIA PACIFIC BIOPSY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 ASIA PACIFIC ENDOSCOPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 ASIA PACIFIC ENDOSCOPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 ASIA PACIFIC LABORATORY TESTS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 ASIA PACIFIC LABORATORY TESTS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 ASIA PACIFIC OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 ASIA PACIFIC OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 CHINA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 26 CHINA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 27 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 28 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 29 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 30 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 31 JAPAN LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 32 JAPAN LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 33 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 34 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 35 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 36 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 37 INDIA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 38 INDIA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 39 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 40 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 41 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 42 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 43 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 44 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 45 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 46 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 47 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 48 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 49 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 50 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 51 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 52 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 53 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 54 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 55 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 56 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 57 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 58 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 59 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 60 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 61 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 62 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 63 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 64 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 65 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 66 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 67 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 69 KEY INFORMATION – BOSTON SCIENTIFIC CORPORATION
TABLE 70 KEY INFORMATION – SIEMENS AG
TABLE 71 KEY INFORMATION – BAYER AG
TABLE 72 KEY INFORMATION - MERCK & CO., INC.
TABLE 73 KEY INFORMATION – SANOFI S.A.
TABLE 74 KEY INFORMATION – NOVARTIS AG
TABLE 75 KEY INFORMATION – PFIZER, INC.
TABLE 76 KEY INFORMATION – RANDOX LABORATORIES LIMITED
TABLE 1 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 2 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 3 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 4 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 5 ASIA PACIFIC HOSPITALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 ASIA PACIFIC HOSPITALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 ASIA PACIFIC LABORATORIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 ASIA PACIFIC LABORATORIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 ASIA PACIFIC OTHER END USERS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 ASIA PACIFIC OTHER END USERS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 12 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 13 ASIA PACIFIC IMAGING MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 ASIA PACIFIC IMAGING MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 ASIA PACIFIC BIOPSY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 ASIA PACIFIC BIOPSY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 ASIA PACIFIC ENDOSCOPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 ASIA PACIFIC ENDOSCOPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 ASIA PACIFIC LABORATORY TESTS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 ASIA PACIFIC LABORATORY TESTS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 ASIA PACIFIC OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 ASIA PACIFIC OTHER DIAGNOSIS TECHNIQUES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 CHINA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 26 CHINA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 27 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 28 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 29 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 30 CHINA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 31 JAPAN LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 32 JAPAN LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 33 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 34 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 35 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 36 JAPAN LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 37 INDIA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 38 INDIA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 39 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 40 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 41 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 42 INDIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 43 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 44 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 45 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 46 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 47 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 48 SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 49 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 50 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 51 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 52 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 53 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 54 SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 55 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 56 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 57 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 58 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 59 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 60 MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 61 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2016 - 2019, USD MILLION
TABLE 62 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, 2020 - 2026, USD MILLION
TABLE 63 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2016 - 2019, USD MILLION
TABLE 64 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY END USER, 2020 - 2026, USD MILLION
TABLE 65 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2016 - 2019, USD MILLION
TABLE 66 REST OF ASIA PACIFIC LIVER DISEASE DIAGNOSTICS MARKET BY DIAGNOSIS TECHNIQUE, 2020 - 2026, USD MILLION
TABLE 67 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 69 KEY INFORMATION – BOSTON SCIENTIFIC CORPORATION
TABLE 70 KEY INFORMATION – SIEMENS AG
TABLE 71 KEY INFORMATION – BAYER AG
TABLE 72 KEY INFORMATION - MERCK & CO., INC.
TABLE 73 KEY INFORMATION – SANOFI S.A.
TABLE 74 KEY INFORMATION – NOVARTIS AG
TABLE 75 KEY INFORMATION – PFIZER, INC.
TABLE 76 KEY INFORMATION – RANDOX LABORATORIES LIMITED
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 RECENT STRATEGIES AND DEVELOPMENTS: ABBOTT LABORATORIES
FIG 3 RECENT STRATEGIES AND DEVELOPMENTS: SIEMENS AG
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 RECENT STRATEGIES AND DEVELOPMENTS: ABBOTT LABORATORIES
FIG 3 RECENT STRATEGIES AND DEVELOPMENTS: SIEMENS AG
